Brian,
I don't think there were any expectations for the Isis drug. PI was not powered for efficacy, and if memory serves it was not given in combination, as it was in this trial. The trial endpoint was for six month survival. If the survival benefit continues by the time ASCO rolls around in May, I think we'd have a definite winner, particularly if it diverges some more from Gemzar alone. I would expect that ISIS will keep following these patients and keep reporting.
One wonders, too, about the analyst call made earlier predicting failure for ISIS' PIII in lung cancer. Very questionable, anecdotal call. Maybe the safest strategy is to watch ISIS into March, when they unblind that trial. If it's still cheap, and that trial turns out OK, I'm buying.
Today I was just looking at the short term trading possibilities. Because in a nutshell, I think there were no expectations, and that the trial went well, and the stock is not reflecting it right now.
Cheers, Tuck |
